Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
54.43 USD | +0.13% | +7.67% | -1.79% |
May. 15 | Stifel Adjusts Price Target on Arcellx to $83 From $82, Maintains Buy Rating | MT |
May. 14 | Evercore ISI Starts Arcellx With Outperform Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.79% | 2.91B | |
+40.80% | 54.04B | |
+43.57% | 41.96B | |
-1.15% | 41.92B | |
-7.59% | 28.35B | |
+12.54% | 26.35B | |
-22.12% | 19B | |
+7.76% | 13B | |
+28.66% | 12.28B | |
+24.89% | 12.19B |
- Stock Market
- Equities
- ACLX Stock
- News Arcellx, Inc.
- Arcellx Says US FDA Placed Clinical Hold on Multiple Myeloma Therapy Phase 2 Trial Following Patient Death